Vascular patent for HealthLinx
Wednesday, 17 September, 2008
HealthLinx [ASX: HTX] has been granted a US patent related to the company's vascular permeability program.
Licensed from the University of Virginia, the patent is related to the inhibition of the p21 activated kinase pathway as a treatment for disorders caused by aberrant vascular permeability.
It has widespread potential applications, including ischemia, stroke or burns.
The patent also forms part of the drug candidate CR014, a potential treatment for acute respiratory distress syndrome (ARDS) that the company is developing with the Canadian-based InSymbiosis.
No effective therapeutic treatments are available for the disease, which has a morbidity rate as high as 40 percent.
HealthLinx and InSymbiosis are preparing to embark on a preclinical development program for CR014.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
